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Vincristine is a core chemotherapeutic drug administered to pediatric acute lymphoblastic leukemia 
patients. Despite its efficacy in treating leukemia, it can lead to severe peripheral neuropathy in a 
subgroup of the patients. Peripheral neuropathy is a debilitating and painful side-effect that can 
severely impact an individual’s quality of life. currently, there are no established predictors of peripheral 
neuropathy incidence during the early stage of chemotherapeutic treatment. As a result, patients who 
are not susceptible to peripheral neuropathy may receive sub-therapeutic treatment due to an empirical 
upper cap on the dose, while others may experience severe neuropathy at the same dose. contrary to 
previous genomics based approaches, we employed a metabolomics approach to identify small sets of 
metabolites that can be used to predict a patient’s susceptibility to peripheral neuropathy at different 
time points during the treatment. Using those identified metabolites, we developed a novel strategy to 
predict peripheral neuropathy and subsequently adjust the vincristine dose accordingly. in accordance 
with this novel strategy, we created a free user-friendly tool, VIPNp, for physicians to easily implement 
our prediction strategy. our results showed that focusing on metabolites, which encompasses both 
genotypic and phenotypic variations, can enable early prediction of peripheral neuropathy in pediatric 
leukemia patients.
Acute lymphoblastic leukemia (ALL) is the most common cancer among children, accounting for approximately 
26% of all pediatric cancers in the USA1. Although the 5-year survival rate of pediatric leukemia patients is as 
high as 86%, the side-effects of the treatment can severely impact the quality of life of survivors2. In particular, 
vincristine, a core chemotherapeutic drug administrated as part of the ALL therapy that has been in use for 
more than 50 years, has a dose-limiting toxicity: peripheral neuropathy. Vincristine-induced peripheral neu-
ropathy (VIPN) is characterized primarily by numbness, tingling, and a painful sensation felt in the hands and 
feet, muscle weakness, and constipation due to its effect on the sensory, motor, and autonomic nerves3–5. In some 
instances, VIPN can be prolonged and may last even after discontinuation of the treatment, impairing patients’ 
motor skills6–9 which results in limitation of their daily life activities for many years after completion of therapy10. 
While VIPN is severe in a subpopulation of patients, another subpopulation experiences negligible neuropathy. 
Currently, there are neither established ways of predicting susceptibility to VIPN in patients, nor ways to treat it 
effectively, resulting in a suboptimal management for both the cohorts. Predicting VIPN susceptibility in patients 
will enable better dosage decision making tools for physicians and in turn may improve the quality of life of these 
patients.
Several researchers have studied the association between genomics and VIPN incidence; however, the major-
ity of the results have been controversial. Most of the studied differences are based on race, CYP3A5, ABC trans-
porter, and, more recently, CEP72 expression. While some studies have reported a significant association between 
race and VIPN incidence11–14, others could not confirm those results5,15. CYP3A5 metabolizes vincristine and 
some studies have reported a significant association between CYP3A5 expression and VIPN13,16,17; however, one 
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study could not establish such an association18. Similarly, there is evidence for association between the ABCB1 
transporter and VIPN19,20; and there also exists evidence to the contrary18. Additional details on the associations 
and non-associations found between VIPN and other variables is addressed by van de Velde et al.4 and Mora et 
al.3. Correlations between pharmacokinetics or other patient-specific co-variates and VIPN have also been eva-
sive due to a large variability in the available interpatient and intrapatient data, making interpretation of these 
pharmacokinetic studies difficult21–25. Recently, significant correlation was discovered of a SNP in the promoter 
region of the CEP72 gene with VIPN, during the maintenance phase of the treatment. CEP72 expression was 
associated with VIPN in human neurons derived from human induced pluripotent stem cells, as well12. While 
some studies have been able to reproduce this finding during the late phase of the treatment26,27, this association 
was not found in the earlier phase of therapy28,29. The literature clearly shows that an established predictor for the 
early stage of the treatment is still lacking.
In this paper, we take a detour from the previous genomics and pharmacokinetics related studies and employ 
a novel approach using metabolomics to predict VIPN at an earlier stage of the treatment. The need to go beyond 
genomics has been raised before30, and, specifically, the role of metabolomics in predicting drug response has 
garnered more attention31,32 in recent years. The recent interest in pairing metabolomics and drug response is 
a result of phenotypic variations that can be captured at the downstream metabolite level. These phenotypic 
variations arise due to differences in environment, lifestyle, stochasticity in biochemical reactions, etc., and may 
be as important as, if not more important than, the upstream genomics to predict drug response30. Information 
transfer for expression of a disease outcome takes place at various stages, starting from transcription of a gene 
to mRNA, then translation to a protein, and, finally, to the synthesis of metabolites. Variations at any stage may 
induce a different response to any drug. Because of this, drug response of a homogeneous population of patients 
with a similar genome may vary. Moreover, variations at the genetic level may not get transferred to the down-
stream metabolite level because of the robustness of the metabolic pathways. Therefore, a metabolomics approach 
is employed to find metabolites that can accurately predict VIPN in a cohort of pediatric patients who underwent 
ALL treatment, with vincristine as the core chemotherapy drug. We determined small sets of metabolites that 
can accurately predict VIPN at different stages of the treatment and used them to develop a strategy to identify 
patients that are highly susceptible to VIPN. Using this strategy, we developed a free user-friendly tool, VIPNp33,34, 
for physicians to apply our models for prediction of VIPN susceptibility at different stages of a patient’s chemo-
therapy treatment.
Results
In this section, we elaborate on our workflow and the results. We categorized the neuropathy data obtained from 
physician evaluations of VIPN severity experienced by patients. We then performed hierarchical clustering to 
differentiate between metabolite profiles measured at both early and late time points of the treatment process. 
Based on their metabolite profiles measured at different time points, we found a small subset of biomarker metab-
olites which was used to build a predictive model of VIPN susceptibility. We were able to identify the molecular 
structure of some of the biomarkers and then performed pathway analysis.
pediatric ALL patient data description. A total of 36 patients’ data was collected. These were pediatric 
patients treated with AALL0932 protocol for B-ALL enrolled in a study from 2010 to 2014 (see Methods for 
details). Vincristine was part of the core chemotherapeutic treatment. All subjects were phenotyped for periph-
eral neuropathy using the Total Neuropathy Score – Pediatric Vincristine (TNS©-PV)35. Twenty-four of the 36 
patients (67%) were phenotyped as patients experiencing high neuropathy (HN), while the remaining 12 patients 
(33%) were classified as patients experiencing low neuropathy (LN) after the treatment completion. Patient 
demographics are described in Table 1. Non-fasting blood samples for these patients were collected prior to 
administration of drugs at three time points of the treatment: during the induction phase (day 8 and day 29) and 
the consolidation phase (around 6 months).
Patients were assessed regularly using the TNS©-PV scoring scheme throughout the 2–3 years of treatment. 
A score less than 3 was considered of low intensity and a score greater than 8 was considered of high intensity. 
A patient was classified as LN if the TNS©-PV intensity remained low throughout the entire duration of the 
treatment which lasted 2–3 years, regardless of the drug amount. A patient was classified as HN if the TNS©-PV 
Day 8 Day 29 and Month 6
HN LN HN LN
Total 24 8 24 12
Females/Males 11/13 4/4 11/13 5/7
Age, in years 
(Mean, SD) 9.6,4.8 4.3,2.4 9.6,4.8 4.4,2.6
BMI, in Kg/m2 
(Mean, SD) 24.4,12.4 14.5,2.6 24.4,12.4 15.1,2.8
Table 1. Patient characteristics were defined according to gender, age, and body mass index (BMI). For the 
day 8 treatment time point, 8 overall low neuropathy (LN) samples were available, while for day 29 and month 
6 time points, 12 LN samples were available. 24 overall high neuropathy (HN) samples were available at all the 
three time points. Age and BMI correspond to that during the start of the treatment. Here, “HN” implies that 
the patient had a Total Neuropathy Score – Pediatric Vincristine (TNS©-PV) greater than 8 at least once, and 
“LN” implies that the patient had a TNS©-PV less than 3 throughout the treatment. SD: standard deviation.
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intensity was high at any time point during the treatment. This classification scheme matched the course of treat-
ment for patients experiencing severe neuropathy. A patient who presents a score of 8 or higher at least once indi-
cates susceptibility for severe neuropathy. The degree of neuropathy may improve during later phases of treatment 
when the drug is given less frequently or after dose modifications have been made for severe VIPN. However, 
these adjustments do not make a patient less susceptible to neuropathy in the future; if a patient was susceptible to 
high neuropathy even once, we classified the patient as HN. As a result of this classification system, patients who 
never had a TNS©-PV greater than 8 but had a TNS©-PV greater than 3 at some point (medium intensity) were 
not considered for the purposes of this study. This classification, as well as, threshold scores of 3 and 8 TNS©-PV 
were delineated to ensure a clear demarcation between patients who were susceptible to severe neuropathy and 
those who experienced negligible neuropathy.
Figure 1 shows how the neuropathy score changed during the course of the treatment time points considered 
and how it compared to the overall neuropathy susceptibility of a patient. At day 8, most of the patients had a low 
TNS©-PV intensity (TNS©-PV less than 3) while the incidence of high neuropathy (TNS©-PV greater than 8) 
increased with time. However, one patient had low TNS©-PV at day 8, high TNS©-PV at day 29, and low again at 
the month 6 time point. Figure 1 shows that by 6 months, 17 out of 24 HN (TNS©-PV greater than 8 at least once 
during the treatment) patients had already experienced high neuropathy, indicating a need for dosage adjustment 
earlier in the treatment process. Consequently, this data shows it is imperative to find biomarkers that enable the 
prediction of overall neuropathy susceptibility during the early stage of the treatment. The focus of this study is 
on finding metabolites that can differentiate between HN and LN during these time points.
Longitudinal versus independent analysis of metabolite profiles. Following the collection of 
patient blood samples, we performed metabolite profiling using liquid chromatography with tandem mass spec-
trometry (LC-MS/MS) (refer to Methods for description). We then analyzed the metabolite profile across the 
three time points, initially using hierarchical clustering. The hierarchical clustering dendogram showed that the 
profiles clustered according to the time points, as shown in Fig. 2. Each branch in the figure corresponds to a sam-
ple. Since the samples were clearly demarcated according to the time points, it implies that the metabolite profiles 
were distinctly expressed at the three time points. Following the hierarchical clustering, we used an algorithm 
to develop a longitudinal support vector classifier (SVC)36 model to further confirm the distinct expression of 
metabolites at the three time points. The algorithm was used to estimate a parameter β according to the following 
equation:































Figure 1. A bar plot showing distribution of the neuropathy score of patients over time. A TNS©-PV less than 
3 corresponds to low, a score between 3 and 8 corresponds to medium, and a score above 8 corresponds to high. 
The first group shows the overall susceptibility of patients to neuropathy (LN versus HN), based on regular 
assessment throughout the entire duration of the treatment that lasted 2–3 years. The next three groups show 
the TNS©-PV intensity at that particular time point. Since patients with an overall medium TNS©-PV intensity 
were not considered in this study, the number of such patients is zero in the first group. Some HN patients had 
medium TNS©-PV intensity (TNS©-PV greater than 3 but lesser than 8) at some points during the treatment, 
as seen in the next three groups.
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where, t1 and t2 are two time points, Y is the neuropathy response, and 
∼X is the metabolite expression matrix. This 
algorithm was used to estimate β by minimizing the error between the predicted and actual response. For differ-
ent combinations of the time points, β was approximately zero, regardless of the initial guess, implying that no 
identical set of metabolites can accurately predict neuropathy at different time points. Based on these two results, 
we hypothesized that different metabolites should be predictive of neuropathy at the different time points leading 
us to analyze the profiles separately as discussed in the next section.
Metabolite selection and model building. In order to find a small set of metabolites that can accurately 
predict overall susceptibility to neuropathy, we used recursive feature elimination (RFE) along with cross valida-
tion to develop a linear SVC model. Since hierarchical clustering and longitudinal SVC modeling (described in 
the previous section) indicated that the metabolite profiles are distinctly expressed across the three time points, 
we applied RFE separately on each of the time point-specific metabolite profile matrix. Our matrix of features 
included metabolite expression and vincristine concentration at the three time points: 5 metabolites at day 8, 46 
metabolites at day 29, and 42 metabolites at the month 6 time point were chosen, with an area under the receiver 
operating characteristics curve (AUROC) of 0.97, 0.95, and 0.96, respectively. The vincristine concentration was 
not one of the selected features at any time point. As shown in Table 2A, these selected metabolites performed 
well at predicting neuropathy at all the three time points, with an average AUROC greater than 0.90 and standard 
deviation of AUROC less than 0.1.
We also performed RFE to find metabolites that can predict time point-specific neuropathy (i.e., high or low 
intensity of TNS©-PV) in patients (Table 2B). Since only 1 patient had high TNS©-PV during day 8, we did not 
perform the analysis on that data set. From the day 29 metabolite profile data, only 2 metabolites were chosen that 
could predict TNS©-PV intensity at that point, with an AUROC of 0.83 (lower accuracy than that obtained from 
the previous analysis shown in Table 2A). From the month 6 data, a small set of metabolites could not be selected; 
Figure 2. A dendogram created based on the Euclidean distance shows that the metabolite profiles are clustered 
according to their corresponding time points. Day 8 and day 29 metabolite profiles belong to the same primary 
branch and are consequently closer to each other.
Time point Predictors AUROC AUROCSD
A
Day 8 5 0.968 0.048
Day 29 46 0.946 0.060
Month 6 42 0.963 0.043
B
Day 29 2 0.831 0.120
Month 6 1955 0.812 0.086
C
Day 8 6 0.938 0.047
Day 29 48 0.861 0.122
Month 6 45 0.923 0.069
Table 2. Metrics obtained by performing RFE on the data sets at the three time points. A: The set of metabolites 
found that can accurately predict overall neuropathy susceptibility (HN versus LN) at these time points before 
manual integration of the chromatogram peaks. B: The set of metabolites found that can accurately predict 
TNS©-PV intensity of either high or low at that specific time point. C: The set of metabolites that can accurately 
predict overall neuropathy susceptibility at the time points after manual integration of peaks. AUROC: 
Area Under Receiver Operating Characteristics Curve, AUROCSD: standard deviations for AUROC. See 
Supplementary Table S1 for sensitivity and specificity corresponding to each of these.
5Scientific RepoRtS |         (2020) 10:9659  | https://doi.org/10.1038/s41598-020-66815-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
1955 metabolites were chosen (Table 2B) with a lower accuracy (AUROC 0.81) as compared to the previous case 
(Table 2A). This implies that the metabolites are more effective in classifying patients based on the overall VIPN 
susceptibility, rather than VIPN intensity at the specific time points.
After selecting the small set of metabolites, that can classify between HN and LN, using RFE, we investigated 
integration of their chromatogram peaks at the corresponding retention times to ensure that they were correctly 
integrated and were not chosen because of any potential error in integration. In order to rigorously validate the 
selected metabolites as biomarkers, we manually reviewed integration of peaks at the retention times of every 
selected metabolite, for every sample, and at all the time points. We used the Agilent ProFinder software for this 
purpose. We found the peaks by matching the m/z and retention time from the metabolite profile matrix to the 
data loaded in ProFinder and then manually visualized each of the peaks. If any integration was not accurate, we 
re-integrated that peak. This resulted in a polished metabolite profile matrix.
We repeated the RFE with this polished metabolite profile matrix to find metabolites that can classify between 
HN and LN. Using this polished data, 6 metabolites were selected at day 8, 48 metabolites at day 29, and 45 
metabolites at month 6 time point, with AUROC of 0.94, 0.86, and 0.92, respectively. Table 2C shows the metrics 
obtained from the model fitting. In this case, the day 8 and month 6 metabolites performed better than those from 
the day 29 data, based on the AUROC and corresponding standard deviation.
To obtain the final list of accurately integrated and predictive metabolites, we chose metabolites that were 
selected both from the polished (2C) and the unpolished data (2A) using RFE on each of them. We further 
discarded the metabolites whose peaks looked erroneous and were difficult to properly integrate. This refined 
procedure provided a final list of 2, 14, and 21 metabolites from day 8, day 29, and month 6 data, respectively. We 
performed repeated cross validation again to train an SVC model using these final set of metabolites. Repeated 
cross validation was performed to estimate the predictability of the model and to find the optimal tuning param-
eter (the “cost” parameter) for the SVC model. The average cross validation AUROC was 0.93, 0.75, and 0.91 for 
day 8, day 29, and month 6 data, respectively. The average ROC’s for the trained models are shown in Fig. 3.
After training the model corresponding to each time point using repeated cross validation, we chose an opti-
mal probability threshold to classify patients based on the output from the SVC model. To find the optimal 
probability threshold, we evaluated the cross validation trained models’ accuracy upon varying the threshold 
value. Evaluation of an appropriate threshold is needed since our data is unbalanced; keeping a threshold of 0.5 
will lead to a bias towards HN. Supplementary Figure S1 shows sensitivity, specificity, Youden’s J statistic, and 
distance from best possible cutoff (i.e. sensitivity and specificity equal to 1) for the day 8, day 29, and month 6 
trained models, where the models were built with the optimal tuning parameters obtained from cross validation. 
We chose the threshold based on the minimum of distance from the best possible cutoff which led to thresholds 
of 0.7, 0.65, and 0.7 for the three respective time points. We finally evaluated the cross validated trained models’ 
performance based on this newly determined threshold. Model performance was based on a confusion matrix 
(provided in Supplementary Table S2) and metrics calculated as shown in Table 3. The metrics shown in Table 3 
show the ability of the models to make predictions when trained using a subset of the data. We have only reported 
cross validation accuracy metrics since we did not have a test data set to assess the performance of our final 
trained model. We finally trained the model using the whole data set and the optimal tuning parameters, which 
can be used to test new patient data.
We used multiple metrics to determine the accuracy and validity of the predictive models. First, the p value 
of the one sided test for an accuracy greater than the No Information Rate is less than 0.05 for all the three time 
point models. This implies that the models predict better than simply random guessing. However, with accuracy 
as a metric, day 8 and month 6 data outperform. The balanced accuracy ((sensitivity + specificity)/2) is higher for 
day 8 and 6 month data as well, indicating that the model for day 8 and month 6 data seems to be more reliable 
in predicting overall VIPN susceptibility. We have developed a user-friendly interface, named VIPNp, to use our 
trained models for day 8 and month 6 time points, freely available at GitHub34 and the Shinyapps server33.
Metabolite structure identification. After we obtained the final list of 2, 14, and 21 metabolites at day 
8, day 29, and month 6, respectively, we wanted to identify the molecular structure of these metabolites based 
on their mass-to-charge ratio (m/z), retention times, and tandem mass spectrometry (MS/MS) spectra. MS/MS 
Figure 3. ROC plots for the final trained models at the three time points. (a) Day 8, (b) Day 29, (c) Month 6. 
AUC: Area Under Curve. CI: Confidence Interval.
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spectra was available for only a subset of the final list: 1 metabolite from the day 8 list, 5 metabolites from the 
day 29 list, and 8 metabolites from the month 6 list. MS/MS spectra was compared to the METLIN37 database 
and the Human Metabolome Database (HMDB)38. No match was found for the day 8 metabolite; for day 29, one 
metabolite matched with Adenosine 5’-monophosphate (AMP) for all the collision energies; for month 6 data, 
one metabolite matched with L-pipecolic acid for one of the collision energies. In order to confirm the identity of 
these metabolites, MS/MS of commercially sourced AMP and pipecolic acid standards was performed to deter-
mine the retention times. The retention times of the external compounds matched with that from the patient 
data (1 min of commercially sourced pipecolic acid versus 0.802 min as identified from the data, 1.4 min versus 
1.77 min for AMP) confirming the identity of these two metabolites.
We used the LC-MS CEU Mass Mediator (CMM) search tool39,40 with m/z value, adduct, and retention 
time inputs in the HMDB database to identify remaining metabolites. The most reasonable options were short-
listed. For example, if one of the searches was a metabolite that could only be found due to consumption of 
alcohol, it was discarded as a potential option since our focus in this study is on pediatric patients. Except for 
1,7-Dimethylguanosine and Phenylalanylproline, all other potentially identified metabolites were at least previ-
ously detected in blood, according to HMDB. Using these approaches, we were able to identify 4 and 9 metab-
olites in the day 29 and month 6 lists, respectively. Tables 4 and 5 define the identified metabolites from the day 
29 and month 6 lists (Supplementary Tables S3, S4 and S5 contain the complete list of metabolites, their mass, 
retention time, and adduct information).
pathway analysis. In order to investigate the relevance of the chosen and identified metabolites, we used 
the pathway analysis tool in Metaboanalyst 4.041,42. We selected the hypergeometric test for over representation 
analysis and the relative-betweeness centrality for pathway topology analysis.
For day 29, two metabolites (Adenosine diphosphate, Adenosine monophosphate) were identified to be part 
of purine metabolism, and one metabolite (N-Acetylornithine) was identified to be part of the arginine bio-
synthesis (details in Supplementary Table S6). Since there were very limited metabolites to perform pathway 
analysis and only one or two of them belonged to a specific pathway which originally consisted of several metab-
olites, none of the metabolite to pathway associations were statistically significant after adjustment of the p values 
required to account for multiple testing. Furthermore, we did not find evidence for the role of these pathways in 
chemotherapy-induced peripheral neuropathy in the existing literature.
For the set of month 6 metabolites, SM(d18:0/16:1(9Z)), Oxidized glutathione, LysoPC(18:1(9Z)), 
and Pipecolic acid were identified to be part of the sphingolipid metabolism, glutathione metabolism, 
Model Metric Day 8 Day 29 Month 6
Accuracy 0.842 0.753 0.815
% CI (0.812, 0.870) (0.720, 0.784) (0.785, 0.843)
No Information Rate 
(NIR) 0.750 0.667 0.667
P-Value 
[Accuracy > NIR] 1.07e-08 3.14e-07 <2.20e-16
Kappa 0.6093 0.448 0.625
McNemar’s Test 
P-Value 3.41e-4 0.600 <2.20e-16
Sensitivity 0.856 0.806 0.754
Specificity 0.800 0.646 0.938
Positive Predictive 
Value 0.928 0.820 0.960
Negative Predictive 
Value 0.650 0.625 0.656
Prevalence 0.750 0.667 0.667
Detection Rate 0.642 0.538 0.503
Detection Prevalence 0.692 0.656 0.524
Balanced Accuracy 0.828 0.726 0.846
Table 3. Cross validation accuracy metrics for the models with optimal tuning using the final selected 
metabolites. These metrics were calculated after choosing the probability thresholds for each of the time points. 
Cost = 4, 0.25, 0.25 for day 8, day 29, and month 6 models, respectively.
HMDB ID Name KEGG ID
HMDB0003357 N-Acetylornithine C00437
HMDB0000757 Glycogen C00182
HMDB0000045 Adenosine monophosphate C00020
HMDB0001341 Adenosine diphosphate C00008
Table 4. Identified metabolites that can accurately predict neuropathy susceptibility at the day 29 time point.
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glycerophospholipid metabolism, and lysine degradation, respectively (details in Supplementary Table S7). 
Again, none of the pathway and metabolite associations were statistically significant after adjustment of the p 
values to account for multiple testing. We, however, did find evidence for the role of sphingolipid metabolism 
in chemotherapy-induced peripheral neuropathy43–45. Moreover, glutathione is a popular antioxidant tested as a 
therapeutic for chemotherapy-induced peripheral neuropathy, with various related studies mentioned in a review 
by Starobova and Vetter46. There is also evidence for the involvement of glycerophospholipid metabolism47 which 
indicates that these metabolites may be biologically relevant to VIPN.
Discussion
Peripheral neuropathy is a painful and debilitating side-effect of vincristine, a common chemotherapeutic drug 
used for treatment of pediatric ALL patients, as well as, many other pediatric and adult cancers. Currently, there is 
no established way of predicting VIPN during the initial stage of the treatment. Identification of specific biomark-
ers will aid in adjusting the vincristine dose according to susceptibility of patients to VIPN in order to improve 
their quality of life. Even though all previous omics related studies have focused on genomics, it is imperative 
to include phenotypic variabilities to find VIPN predictors given their known impact on drug response. In this 
study, we investigated the role of metabolites in predicting susceptibility of ALL pediatric patients to VIPN.
We performed metabolite profiling of ALL patients at three time points during the treatment: day 8, day 29, 
and month 6. First, we found that the metabolite profiles were distinctly expressed at the three time points, as 
shown by hierarchical clustering (Fig. 2) and longitudinal SVC modeling, indicating that the overall metabolite 
profile varied as a direct response to the treatment. Second, preliminary analysis using RFE resulted in sets of 5, 
46, and 42 metabolites that accurately predicted overall VIPN susceptibility. Since the vincristine concentration 
was not one of the selected features from RFE, we concluded that regardless of the vincristine concentration at the 
time points, a small set of metabolites can accurately predict overall neuropathy susceptibility in these patients 
at these time points. Third, we manually integrated chromatogram peaks of these selected metabolites and per-
formed RFE again with the polished matrix. Subsequently, we chose the metabolites that overlapped from the 
analysis with unpolished and polished data. Then, final sets of 2, 14, and 21 metabolites were found that could 
predict overall VIPN susceptibility at day 8, day 29, and month 6, respectively.
Metabolites could not predict time point-specific TNS©-PV intensity as accurately as overall susceptibility to 
VIPN (LN versus HN). This further strengthened our hypothesis that specific downstream metabolites can be 
potential biomarkers of overall neuropathy susceptibility due to treatment with vincristine. Furthermore, the final 
models built with the chosen metabolites were more accurate in predicting neuropathy at day 8 and month 6 as 
compared to the model built for the day 29 data (Table 3), implying that our developed predictive models can be 
used to evaluate VIPN susceptibility at the day 8 and month 6 time points during the treatment.
Based on the final developed models at the day 8 and month 6 time points, we present a framework for pre-
dicting a patient’s overall VIPN susceptibility during ALL treatment (Fig. 4). On day 8 of the treatment, blood 
samples can be collected for metabolite profiling, specifically to obtain expression of the 2 chosen metabolites. The 
expression of these metabolites can be used to predict overall neuropathy susceptibility from our trained model. 
If the output of the model is a probability greater than the threshold value of 0.7, the physician may need to lower 
the vincristine dose as that sample might correspond to an HN patient. A follow up evaluation can be performed 
after 6 months by obtaining expression of the 21 chosen metabolites (Supplementary Table S5). If the output from 
the two trained models is consistently a probability greater than 0.7, the physician could consider lowering the 
vincristine dose. This framework can aid in vincristine dose decision making for the physicians. Our user-friendly 
tool, VIPNp33,34, can be used to execute this strategy.
In the foregoing suggested strategy, a significant caveat is that these models can only classify patients as sus-
ceptible to HN or LN. Some patients might be susceptible to “medium” VIPN (TNS©-PV greater than 3 but lesser 
than 8) during the treatment. Such cases have not been included here, implying that the models have limited pre-
dictability and that they should be used with caution. As a result, we only suggest that if the output of the model is 
greater than 0.7 at both day 8 and month 6 predictions, then there may be a need to adjust vincristine dose, since 
such patients are most likely classified as HN. It must also be noted that developing a strategy to balance efficacy 
and toxicity of vincristine would require further investigation before a standard protocol for physicians can be 
developed, in careful consideration with ALL experts.
Even though we finalized a list of metabolites using RFE (Supplementary Tables S3, S4, and S5), we could 
not identify all of them. This greatly reduced our capability to find the biological relevance of these chosen 
HMDB ID Name KEGG ID









Table 5. Identified metabolites that can accurately predict neuropathy susceptibility at the month 6 time point.
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metabolites. We could not obtain MS/MS spectra for all of them, which may be a result of their presence in 
smaller quantities. Even after obtaining the MS/MS spectra, we could not find matches from existing databases 
for most of these metabolites. As a result, we only used the available m/z value, retention time, and adduct infor-
mation for the remaining unidentified metabolites, which does not ensure that we have identified the metabolites 
correctly. For a thorough identification, MS/MS spectra is needed for all of the chosen metabolites and subse-
quently the retention times of those compounds need to be validated using authentic standards. Since only a few 
metabolites could be identified and consequently used for pathway analysis, none of the associations between the 
metabolites and their pathways found were statistically significant. Even though some of the identified metabo-
lites for the month 6 data belonged to pathways that are relevant to chemotherapy-induced peripheral neuropa-
thy, their biological relevance could not be established with certainty.
The peak integration of chromatograms also needs to be interpreted with caution. We observed that some 
peaks may not be integrated correctly or may simply be difficult to integrate for only a few metabolites. This has 
two implications: 1) The chosen metabolites may be predictive of neuropathy because they were improperly 
integrated. We eliminated this possibility by manually integrating and repeating RFE with a polished metabolite 
profile matrix. 2) Some potential biomarker metabolites might not have been chosen because of poor integration. 
It is not feasible to manually inspect every peak for every sample given that there were approximately 2000 metab-
olites and 104 samples (including all the time points), leaving a possibility that all potential predictors might 
not have been identified. Regardless, the current metabolites found at day 8 and month 6 are certainly potential 
predictors since they accurately predict VIPN susceptibility.
It should also be noted that the metabolite profile matrix is defined as high dimensional–with several metab-
olites and very few samples. This leaves a possibility that, despite using feature selection machine learning algo-
rithms, some potential metabolites may have been overlooked. Moreover, we do not have balanced samples; 
having an equal number of high and low neuropathy patients will allow for a more accurate model. We also do not 
have a test set to validate our model. It is critical to perform this study with more samples and additional datasets 
in order to test and validate our model. VIPNp33,34 can be used to test our trained models on new datasets in the 
future. There is also a need to include “medium” neuropathy patients to accurately predict multiple outcomes of 
the treatment. Since this is the first metabolomics based pilot study for VIPN, we only focused on HN and LN 
patients to explore the potential of this approach in predicting VIPN susceptibility.
It should also be acknowledged that the average age of LN and HN patients were different (4.4 and 9.6 years, 
respectively). It would, thus, be interesting to explore the role of puberty in VIPN incidence. To investigate the 
effect of puberty on the metabolite profiles, we performed hierarchical clustering which did not show a demar-
cation of metabolite profiles based on the cutoff age of 10 years (see Supplementary Figs. S2, S3, and S4). We still 
cannot rule out the role of puberty in this case, which could have been addressed better if all the selected metab-
olites could be identified. The currently identified metabolites and their corresponding pathways are not directly 
related to puberty. This would require further investigation in the future.
Despite these limitations, our preliminary study has shown that ALL treatment can alter the metabolite pro-
files, and a few selected metabolites can accurately predict the overall VIPN susceptibility. We have also provided 
a strategy (Fig. 4) to adjust the vincristine dose based on VIPN susceptibility at two time points: day 8 and 
month 6. Our work shows that metabolomics can aid in predicting VIPN susceptibility during the early stage 
of treatment. Although it must be admitted that our prediction of high and low neuropathy could have had a 
stronger statistical backing with a larger cohort of patients, we contend that the numbers in this study were not 
so unreasonably small as to challenge this major conclusion. Based on an exhaustive literature review, all previ-
ous studies have only focused on genomics and pharmacokinetics in the prediction of chemotherapy-induced 
peripheral neuropathy with the exception of one proteomics study48. This pilot study is the first of its kind focused 
on metabolomics to predict VIPN. In order for this methodology to be more effective, we need a balanced and 
Figure 4. A workflow showing a potential vincristine dose decision making strategy based on the trained SVC 
models. Blood samples of patients can be collected at day 8 and month 6 time points of the treatment. Samples 
can then be analyzed using mass spectrometry for metabolite profiling of the selected 2 and 21 metabolites at 
the day 8 and month 6 time points, respectively. The metabolite profile data can then be used to predict overall 
neuropathy susceptibility from our trained SVC models. If the model output probability is greater than a 
threshold value of 0.7, the patient might be susceptible to overall high neuropathy (HN). This strategy enables 
identification of patients susceptible to HN. The vincristine dose for HN patients may require adjustment.
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large number of fasting samples, accurate integration of chromatogram peaks, MS/MS spectra for all the chosen 
metabolites, and a more exhaustive database to identify these metabolites.
Peripheral neuropathy is not just limited to vincristine but is a dose-limiting toxicity of several other chemo-
therapy drugs (paclitaxel, taxane, and cisplatin), as well. A problem of this scale requires expertise and continued 
collaboration of individuals across multiple disciplines. An integrative approach involving better quantitation 
of all the omics data, large patient cohorts, careful phenotyping of patient data, and state of the art machine 
learning and statistical techniques is necessary in order to find a robust prediction of VIPN and any other 
chemotherapy-induced peripheral neuropathy, even before the start of the treatment.
Methods
ALL patient data collection. Children with newly diagnosed precursor B-cell ALL were recruited from 
four academic medical centers: Indiana University School of Medicine/Riley Hospital for Children, the University 
of Michigan Comprehensive Cancer Center/Mott Children’s Hospital, Vanderbilt University Medical Center/
Monroe Carell Jr. Children’s Hospital, and George Washington University/Children’s National Medical Center49. 
Participants were between the ages of 1 and 18 at the time of diagnosis and received vincristine according to a 
Children’s Oncology Group (COG) treatment trial for acute lymphoblastic leukemia. The standard vincristine 
dosage received was 1.5 mg/m2 (capped at 2-mg maximum dose). Toxicity-based dose modifications were defined 
according to the specific COG protocol guiding the individual child’s leukemia treatment. Patients were excluded 
if they had any of the following criteria: baseline peripheral neuropathy score greater than grade 1 per the NCI 
CTCAE©version 4.0; currently receiving erythropoietin, itraconazole, or vitamin supplement greater than 100% 
of the recommended daily allowance; Down’s syndrome; pregnancy; or a history of coexisting serious illness 
that would limit neurological assessments. The protocol was reviewed and approved by the Institutional Review 
Boards at all four participating centers. All the methods were performed in accordance with the relevant guide-
lines and regulations. Informed consent was obtained from a parent and/or legal guardian for study participation.
Metabolomics sample preparation and extraction. Protein removal and sample extraction were per-
formed by adding 200 μL methanol to 100 μL of plasma. Solutions were sonicated for 2 minutes, chilled at −20 °C 
for 1 hour, and centrifuged at 16,000 × g for 8 minutes. The supernatants were transferred to separate vials and 
evaporated to dryness in a vacuum concentrator. The dried fractions were reconstituted in 75 μL of diluent com-
posed of 95% water and 5% acetonitrile, containing 0.1% formic acid. Solutions were sonicated for 5 minutes, 
centrifuged at 16,000 × g for 8 minutes, and the supernatants were transferred to plastic HPLC total recovery 
autosampler vials.
HpLc-MS analysis of metabolomics samples. Separations were performed on an Agilent 1290 system 
(Palo Alto, CA), with a mobile phase flow rate of 0.45 mL/min50. The metabolites were assayed using a Waters 
HSS T3 UPLC column (1.8 μm, 2.1 × 100 mm), where the mobile phase A and B were 0.1% formic acid in ddH2O 
and acetonitrile, respectively. Initial conditions were 100:0 A:B, held for 1 minute, followed by a linear gradient to 
70:30 at 16 min, then 5:95 at 21 min. Column re-equilibration was performed by returning to 100:0 A:B at 22 min-
utes and holding until 27 minutes. The mass analysis was obtained using an Agilent 6545 Q-TOF mass spectrom-
eter with electrospray ionization (ESI) capillary voltage +3.2 kV, nitrogen gas temperature 325 °C, drying gas flow 
rate 8.0 L/min, nebulizer gas pressure 30 psig, fragmentor voltage 130 V, skimmer 45 V, and OCT RF 750 V. Mass 
data from m/z 70–1000 scans were collected at 5 Hz using Agilent MassHunter Acquisition software (v. B.06). 
Mass accuracy was improved by infusing Agilent Reference Mass Correction Solution (G1969-85001). To assist 
with compound identification, MS/MS was performed in a Data-dependent Acquisition mode. Five precursors 
per cycle were obtained using fixed collision energies of 10, 20, and 40 eV.
Peak deconvolution, integration, and alignment was performed using Agilent ProFinder (v. B.06). Peak anno-
tations were performed using the METLIN (www.metlin.scripps.edu) and HMDB (www.hmdb.ca) metabolite 
databases, with a mass error of less than 15 ppm.
Vincristine quantitation. Sample preparation. 100 μL plasma was pipetted to a microcentrifuge tube51. 
Protein precipitation was performed by adding 200 μL cold methanol. The mixture was vortexed for 2 minutes, 
chilled at −20 °C for 1 hour, and then centrifuged at 13,000 g for 8 minutes. Supernatant was transferred to a fresh 
microcentrifuge tube and vacuum concentrated to dryness. Reconstituted in 75 μL of diluent (95% water and 5% 
acetonitrile, with 0.1% formic acid), sonicated for 5 minutes, centrifuged at 13,000 rpm for 8 minutes, and super-
natant was transferred to HPLC vials.
HPLC/MS-MS analysis. Vincristine plasma levels were quantitated by HPLC/MS-MS. Separation was per-
formed on an Agilent Rapid Res 1200 HPLC system using an Agilent Zorbax XDB-C18 (2.1 × 50 mm, 3.5 μm) 
column. Mobile phase A was water with 0.1% formic acid and mobile phase B was acetonitrile with 0.1% formic 
acid. Initial conditions were 95:5 A:B, held for 0.5 minute, followed by a linear gradient to 0:100 at 8 min, and 
held until 10 min. Column re-equilibration was performed by returning to 95:5 A:B at 11 minutes and held until 
15 minutes. Column flow rate was 0.3 mL/min. Retention time for vincristine was 5.9 minutes.
Analytes were quantified by MS/MS utilizing an Agilent 6460 triple quadrupole mass spectrometer with elec-
trospray ionization (ESI). Quantitation was based on Multiple Reaction Monitoring (MRM). ESI positive mode 
was used with a transition of 825.2 to 807.7 (quantifier) and 825.2 to 765.3 (qualifier), with a collision energy (CE) 
of 45 and 40 V, respectively. A fragmentor energy of 135 V and a dwell time of 80 ms was used. Source parameters 
were as follows: nitrogen gas temperature = 330 °C and flow rate = 10 L/min, nebulizer pressure = 35 psi, sheath 
gas temperature = 250 °C, sheath gas flow rate = 7 L/min, and capillary potential = 3.5 kV. All the data were col-
lected and analyzed with Agilent MassHunter B.03 software. Quantitation was based on a 6 point standard curve, 
1 0Scientific RepoRtS |         (2020) 10:9659  | https://doi.org/10.1038/s41598-020-66815-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
with concentration range from 0.1 to 500 ng/mL, by spiking vincristine into unmedicated human plasma (Sigma). 
Standard curves were fit to a quadratic function, with a 1/x curve fit weighting. Correlation coefficients >0.99 
were obtained.
Metabolite profiling data analysis. Data analysis was performed in R52. First, metabolites that were not 
present in at least 75% of the patients in at least one group were discarded. Subsequently, missing data imputation 
was performed using a modified k-nearest neighbours (KNN) imputation as specified in53. Impute package in R 
was used to perform the KNN imputation54. Hierarchical clustering was performed using hclust, with ward.D2 
as the method and Euclidean distance as the metric. For metabolite selection, recursive feature elimination (RFE) 
along with repeated 5-fold cross validation support vector classifier was used. Repetition was done 20 times. This 
was further iterated 100 times and the model was chosen based on highest AUROC and lowest specificity stand-
ard deviation. For recursive feature elimination, all sizes of number of predictors between 1 to 50 were allowed. 
Caret55 package from R was used for this. The method specified in caret for this algorithm is svmLinear2, from 
the package e107156. Tunelength was kept as 1 and hence the cost parameter was fixed to 0.25. SVM with linear 
kernel was chosen because more tuned parameters would be needed for nonlinear kernels. Since our dataset had 
few samples, that may have lead to overfitting. Final model fitting results specified in Table 2 were based on resa-
mpling from bootstrapping 25 times, using the selected number of predictors. This was the default model fitting 
mode in caret while performing RFE.
For model training after finalizing the set of metabolites, we trained using 5-fold repeated cross validation, 
repeated 20 times. The metric for accuracy was kept as AUROC. Here, tuneLength was kept as 10. Cost function 
of the SVM model was tuned using this. After model training, for deciding the probability threshold, thresholds 
between 0.5 and 1 were explored. The one corresponding to minimum distance from perfect sensitivity and spec-
ificity (i.e. both of them equal to 1) was chosen. Subsequently, confusion matrix and its metrics were generated 
using caret package’s confusion matrix generator.
Data availability
Our trained models are available on https://github.com/parulv1/VIPNp. The metabolite profiles and codes are 
available on https://github.com/parulv1/Metabolomics-Data.
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